905 related articles for article (PubMed ID: 10678548)
41. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
Littlejohn T; Mroczek W; Marbury T; VanderMaelen CP; Dubiel RF
Can J Cardiol; 2000 Sep; 16(9):1123-32. PubMed ID: 11021956
[TBL] [Abstract][Full Text] [Related]
42. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Jacobsen P; Andersen S; Jensen BR; Parving HH
J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of benazepril plus hydrochlorothiazide versus benazepril alone in hypertensive patients unresponsive to benazepril monotherapy.
Holwerda K; Hoogma RP; Oldenbroek C; Huige RC; Wester A; Rijnierse JM
Clin Ther; 1994; 16(6):942-51. PubMed ID: 7697691
[TBL] [Abstract][Full Text] [Related]
44. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
[TBL] [Abstract][Full Text] [Related]
45. Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients.
Fogari R; Malamani G; Corradi L; Mugellini A; Preti P; Zoppi A; Derosa G
Adv Ther; 2010 Jan; 27(1):48-55. PubMed ID: 20174905
[TBL] [Abstract][Full Text] [Related]
46. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
[TBL] [Abstract][Full Text] [Related]
47. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
Seeman T; Pohl M; Misselwitz J; John U
Kidney Blood Press Res; 2009; 32(6):440-4. PubMed ID: 20016211
[TBL] [Abstract][Full Text] [Related]
48. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.
Solomon SD; Janardhanan R; Verma A; Bourgoun M; Daley WL; Purkayastha D; Lacourcière Y; Hippler SE; Fields H; Naqvi TZ; Mulvagh SL; Arnold JM; Thomas JD; Zile MR; Aurigemma GP;
Lancet; 2007 Jun; 369(9579):2079-87. PubMed ID: 17586303
[TBL] [Abstract][Full Text] [Related]
49. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
[TBL] [Abstract][Full Text] [Related]
50. [Effects of benazepril and valsartan on erythropoietin levels in patients with essential hypertension].
Guo LL; Li M; Wang AH
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1761-3. PubMed ID: 22027785
[TBL] [Abstract][Full Text] [Related]
51. Strict blood-pressure control and progression of renal failure in children.
; Wühl E; Trivelli A; Picca S; Litwin M; Peco-Antic A; Zurowska A; Testa S; Jankauskiene A; Emre S; Caldas-Afonso A; Anarat A; Niaudet P; Mir S; Bakkaloglu A; Enke B; Montini G; Wingen AM; Sallay P; Jeck N; Berg U; Caliskan S; Wygoda S; Hohbach-Hohenfellner K; Dusek J; Urasinski T; Arbeiter K; Neuhaus T; Gellermann J; Drozdz D; Fischbach M; Möller K; Wigger M; Peruzzi L; Mehls O; Schaefer F
N Engl J Med; 2009 Oct; 361(17):1639-50. PubMed ID: 19846849
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness and safety of high-dose valsartan monotherapy in hypertension treatment: the ValTop study.
Parati G; Asmar R; Bilo G; Kandra A; Di Giovanni R; Mengden T
Hypertens Res; 2010 Oct; 33(10):986-94. PubMed ID: 20686486
[TBL] [Abstract][Full Text] [Related]
53. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
Kincaid-Smith P; Fairley KF; Packham D
Nephrol Dial Transplant; 2004 Sep; 19(9):2272-4. PubMed ID: 15252156
[TBL] [Abstract][Full Text] [Related]
54. [Efficacy of benazepril after failure of the first antihypertensive treatment].
Francillon A; Heintzmann F; Serrurier D
Therapie; 1994; 49(2):95-9. PubMed ID: 7817356
[TBL] [Abstract][Full Text] [Related]
55. A comparison of valsartan and captopril in patients with essential hypertension in Indonesia.
Prabowo P; Arwanto A; Soemantri D; Sukandar E; Suprihadi H; Parsudi I; Markum MS; Kabo P; Atmoko R; Prodjosudjadi W
Int J Clin Pract; 1999 Jun; 53(4):268-72. PubMed ID: 10563070
[TBL] [Abstract][Full Text] [Related]
56. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy.
Stergiou GS; Makris T; Papavasiliou M; Efstathiou S; Manolis A
J Hypertens; 2005 Apr; 23(4):883-9. PubMed ID: 15775795
[TBL] [Abstract][Full Text] [Related]
57. Comparison of the effects of nebivolol and valsartan on BP reduction and sleep apnoea activity in patients with essential hypertension and OSA.
Heitmann J; Greulich T; Reinke C; Koehler U; Vogelmeier C; Becker HF; Schmidt AC; Canisius S
Curr Med Res Opin; 2010 Aug; 26(8):1925-32. PubMed ID: 20560730
[TBL] [Abstract][Full Text] [Related]
58. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
Agarwal R; Siva S; Dunn SR; Sharma K
Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
[TBL] [Abstract][Full Text] [Related]
59. [Risk for hyperkalemia during long-term treatment with angiotensin-converting enzyme inhibitors in insulin-dependent type 2 diabetics in relation to the glomerular filtration rate].
Raml A; Schmekal B; Grafinger P; Biesenbach G
Dtsch Med Wochenschr; 2001 Nov; 126(47):1327-30. PubMed ID: 11719857
[TBL] [Abstract][Full Text] [Related]
60. Effect of combination therapy with atenolol and the angiotensin-converting enzyme inhibitor benazepril.
Bursztyn M; Gavras I; Gourley L; DeSilva J; Whalen J; Gavras H
Clin Ther; 1994; 16(3):429-36. PubMed ID: 7923309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
